FOREST LABORATORIES, Inc. (NY:FRX)
29.57
+0.46 (1.58%)
| FOREST LABORATORIES, Inc. (NY:FRX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $29.11 | 52 Week High | $30.56 | ||
| Open | $29.19 | 52 Week Low | $18.37 | ||
| Day High | $29.62 | P/E | 12.27 | ||
| Day Low | $28.93 | EPS | $2.41 | ||
| Volume | 3,444,409 | ||||
| More FRX Info: Chart SEC Filings Profile Historical Options | |||||
Forest Laboratories Inc. Summary
Forest Laboratories, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of branded and generic forms of ethical drug products, as well as non-prescription pharmaceutical products.
Executives
Howard Solomon - Chairman, CEO
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| CEPH | 6 | STT | 6 |
| SEPR | 5 | RF | 5 |
| MRX | 5 | CAT | 5 |
| ENDP | 5 | MYL | 4 |
| BLK | 4 | CYPB | 4 |
| UTX | 4 | AMTD | 4 |
Entities who have mentioned FRX
- Citi | View Related Stories »
- UBS | View Related Stories »
- JPMorgan | View Related Stories »
- Deutsche Bank | View Related Stories »
- Goldman Sachs | View Related Stories »
- Morgan Stanley | View Related Stories »
- Banc of America | View Related Stories »
- Trading Radar | View Related Stories »
- Jefferies & Co | View Related Stories »
- Merrill Lynch | View Related Stories »
- Credit Suisse | View Related Stories »
- Collins Stewart | View Related Stories »
- Barclays | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Wachovia | View Related Stories »
- RBC Capital | View Related Stories »
- Needham & Co | View Related Stories »
- Dividend | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Barry Rosenstein | View Related Stories »
- Friedman, Billings, Ramsey | View Related Stories »
- Carl Icahn | View Related Stories »
- Crude Oil | View Related Stories »
- Warburg Pincus | View Related Stories »
- Cowen & Co | View Related Stories »
View All Major News StreetInsider.com Major News for FRX
- Forest Laboratories (FRX) Reports EPS $0.85 Ex-Items; Guides FY09 EPS
- Forest Labs (FRX) Tops Q2 View By 5c
- Forest Labs (FRX) Reports Mixed Q4 Results; Guides
View All ReportsStreetInsider.com Reports on FRX
- Ironwood Pharma and Forest Labs (FRX) Announces Positive Top-Line Results for Linaclotide in Two Phase 3's
- Deutsche Bank Upgrades Freeport-McMoRan (FCX) to Buy; More Positive on Stock After 2 Strong Quarters
- Notable Analyst Rating Changes 10/21: CAT, CSCO, SYK, FRX Upgraded; LMT, EAT, NVS Downgraded
- Cowen & Co Upgrades Forest Laboratories (FRX) to Outperform
- Forest Laboratories (FRX) Reports EPS $0.85 Ex-Items; Guides FY09 EPS
View All Press ReleasesCompany Press Releases on FRX
- Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation
- Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
- Trading Review for Discovery Laboratories Inc. Issued by Beacon Equity
- Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per Share of $0.61, Including a Net $0.24 Per Share Charge for One-Time Items
- Forest Laboratories and Cypress Bioscience Announce Study Shows Patients Treated with Savella Experience Improvements in Pain and Physical Function
StreetInsider Reports on FRX by Category
View All BlogsBlogs on FRX
- Billionaire Validation (x2): Barnes & Noble, Forest Labs
- Forest Laboratories: Steady Growth in Sales and Earnings
- Tuesday Options Update: RRI, WFR, CAR & FRX
- Forest Laboratories Inc. F2Q10 (Qtr End 30/09/09) Earnings Call Transcript
- Analyst upgrades, downgrades and initiations: AAPL, BAC, C, CMCSA, NOK, USB ...
Comments on recent FRX articles
Comments on FRX
No comments are currently available.
on Sep 11, 2009
at 12:55 PM is this going to happen ? i have bought it for 10.34 based on this news
Article: Jazz Pharmaceuticals (JAZZ) Continues Ramp Higher with Rumors Abound